Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

IF 2.4 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI:10.1097/CCO.0000000000001252

Zahra Noordally, Magdalena Mileva, Alain Hendlisz, Ioannis Karfis

{"title":"Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.","authors":"Zahra Noordally, Magdalena Mileva, Alain Hendlisz, Ioannis Karfis","doi":"10.1097/CCO.0000000000001252","DOIUrl":null,"url":null,"abstract":"Purpose of review: Systemic radionuclide therapy has become a cornerstone in the management of advanced gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs). Following the establishment of β-emitting peptide receptor radionuclide therapy (PRRT) as an effective treatment for somatostatin receptor positive NETs, recent clinical and translational advances have substantially expanded its therapeutic scope. Several pivotal randomised trials published within the past 18 months justify a reassessment of radionuclide treatment strategies in GEP-NETs.Recent findings: Recently published results of randomised phase III trials support a broader and more strategic use of PRRT, such as in selected high-grade well differentiated NETs. Direct comparisons of PRRT and targeted therapies redefine therapeutic sequencing. Radiosensitising combinations and next-generation theranostic platforms, including alpha-emitting radionuclides, are entering late-phase development.Summary: Radionuclide therapy in GEP-NETs is transitioning from a late-line option toward a flexible, biology-driven treatment strategy with important implications for clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 4","pages":"351-358"},"PeriodicalIF":2.4000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001252","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Systemic radionuclide therapy has become a cornerstone in the management of advanced gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs). Following the establishment of β-emitting peptide receptor radionuclide therapy (PRRT) as an effective treatment for somatostatin receptor positive NETs, recent clinical and translational advances have substantially expanded its therapeutic scope. Several pivotal randomised trials published within the past 18 months justify a reassessment of radionuclide treatment strategies in GEP-NETs.

Recent findings: Recently published results of randomised phase III trials support a broader and more strategic use of PRRT, such as in selected high-grade well differentiated NETs. Direct comparisons of PRRT and targeted therapies redefine therapeutic sequencing. Radiosensitising combinations and next-generation theranostic platforms, including alpha-emitting radionuclides, are entering late-phase development.

Summary: Radionuclide therapy in GEP-NETs is transitioning from a late-line option toward a flexible, biology-driven treatment strategy with important implications for clinical practice.

查看原文本刊更多论文

全身放射性核素治疗胃、肠、胰神经内分泌肿瘤。

综述目的：全身放射性核素治疗已成为晚期胃-肠-胰神经内分泌肿瘤（GEP-NETs）治疗的基石。随着β-发射肽受体放射性核素疗法（PRRT）作为生长抑素受体阳性NETs的有效治疗方法的确立，近年来的临床和转化进展大大扩大了其治疗范围。在过去18个月内发表的几项关键随机试验证明重新评估GEP-NETs中的放射性核素治疗策略是合理的。最近的发现：最近发表的随机III期试验结果支持更广泛和更具战略性的使用PRRT，例如在选定的高级别分化良好的NETs中。PRRT和靶向治疗的直接比较重新定义了治疗顺序。放射增敏组合和下一代治疗平台，包括α -放射核素，正在进入后期开发阶段。总结：GEP-NETs中的放射性核素治疗正在从晚期选择向灵活的、生物学驱动的治疗策略转变，对临床实践具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.